Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.
Cardiac
Light chain amyloidosis
Minimal residual disease
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
19
04
2024
accepted:
21
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Minimal residual disease (MRD) is of growing interest in light chain (AL) amyloidosis and is associated with higher rates of cardiac response. A new graded cardiac response criteria has been proposed for better assessment of cardiac improvement. We evaluated MRD status in 63 patients with cardiac AL amyloidosis using next generation flow cytometry (sensitivity ≥ 1*10
Identifiants
pubmed: 39485557
doi: 10.1007/s10238-024-01511-z
pii: 10.1007/s10238-024-01511-z
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Proteasome Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
250Subventions
Organisme : Natural Science Foundation of Shanghai
ID : 22ZR1411400
Informations de copyright
© 2024. The Author(s).
Références
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79–89.
doi: 10.1001/jama.2020.5493
pubmed: 32633805
Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57.
doi: 10.1093/qjmed/91.2.141
pubmed: 9578896
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.
pubmed: 7878478
Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787–9.
doi: 10.1016/S0140-6736(03)13396-X
pubmed: 12781539
Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78–84.
doi: 10.1046/j.1365-2141.2003.04433.x
pubmed: 12823348
Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005;36(7):597–600.
doi: 10.1038/sj.bmt.1705106
pubmed: 16044137
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.
doi: 10.1200/JCO.2011.37.7614
pubmed: 23091105
Sidana S, Muchtar E, Sidiqi MH, et al. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Am J Hematol. 2020;95(5):497–502.
doi: 10.1002/ajh.25746
pubmed: 32010993
pmcid: 8019396
Palladini G, Paiva B, Wechalekar A, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021;11(2):34.
doi: 10.1038/s41408-021-00428-0
pubmed: 33594045
pmcid: 7887224
Li X, Huang B, Liu J, Chen M, Gu J, Li J. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis. J Cancer Res Clin Oncol. 2022;148(4):913–9.
doi: 10.1007/s00432-021-03653-z
pubmed: 33966111
Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020;4(5):880–4.
doi: 10.1182/bloodadvances.2019001331
pubmed: 32130406
pmcid: 7065470
Kastritis E, Kostopoulos IV, Theodorakakou F, et al. Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid. 2021;28(1):19–23.
doi: 10.1080/13506129.2020.1802713
pubmed: 32783569
Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854–8.
doi: 10.1182/blood-2005-11-4385
pubmed: 16434487
Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–9.
doi: 10.1038/s41375-018-0060-x
pubmed: 29581546
Muchtar E, Dispenzieri A, Wisniowski B, et al. Graded cardiac response criteria for patients with systemic light chain amyloidosis. J Clin Oncol. 2023;41(7):1393–403.
doi: 10.1200/JCO.22.00643
pubmed: 36215675
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.
doi: 10.1200/JCO.2004.03.029
pubmed: 15365071
Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.
doi: 10.1182/blood-2012-12-473066
pubmed: 23479568
Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–5.
doi: 10.1182/blood-2015-01-620302
pubmed: 25987656
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.
doi: 10.1200/JCO.2011.38.5724
pubmed: 22331953
pmcid: 3675680
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Shen KN, Feng J, Huang XF, et al. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment. Ann Hematol. 2017;96(12):2089–94.
doi: 10.1007/s00277-017-3132-5
pubmed: 28956112
Manwani R, Foard D, Mahmood S, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018;103(4):e165–8.
doi: 10.3324/haematol.2017.178095
pubmed: 29305414
pmcid: 5865426
Gustine JN, Staron A, Mendelson L, et al. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023;7(20):6080–91.
doi: 10.1182/bloodadvances.2023010324
pubmed: 37581513
pmcid: 10582303
Muchtar E, Dispenzieri A, Jevremovic D, et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2020;27(1):13–6.
doi: 10.1080/13506129.2019.1666709
pubmed: 31544536
Kastritis E, Kostopoulos IV, Terpos E, et al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018;8(5):46.
doi: 10.1038/s41408-018-0086-3
pubmed: 29795385
pmcid: 5967299
Sidana S, Dispenzieri A, Murray DL, et al. Revisiting complete response in light chain amyloidosis. Leukemia. 2020;34(5):1472–5.
doi: 10.1038/s41375-019-0664-9
pubmed: 31772296